Review
Biochemistry & Molecular Biology
Alessio Gerussi, Ambra Natalini, Fabrizio Antonangeli, Clara Mancuso, Elisa Agostinetto, Donatella Barisani, Francesca Di Rosa, Raul Andrade, Pietro Invernizzi
Summary: Drug-induced liver injury (DILI) is a challenging clinical event with various phenotypes and limited diagnostic and therapeutic tools. Recent advancements in genomics and immunology offer insights into the molecular aspects of DILI, helping to improve understanding and research in this field.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Yu-Ting Xiong, Jian-Fei Wang, Xiao-Xia Niu, Yi-Ming Fu, Ke-Xin Wang, Chun-Yan Wang, Qian-Qian Li, Jian-Jun Wang, Jun Zhao, Dong Ji
Summary: Clinical characteristics and risk factors associated with the severity of drug-induced liver injury (DILI) in elderly patients were identified. The presence of autoimmunity was found to be associated with a more serious state of DILI.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Pharmacology & Pharmacy
Meng Li, Qiong Luo, Yanyan Tao, Xin Sun, Chenghai Liu
Summary: This article reviews the accumulated literature on drug-induced liver injury (DILI) with evidence-based medicine researches and discusses the limitations of clinical studies and the prospective development for DILI therapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Sabine Weber, Alexander L. Gerbes
Summary: Drug-induced liver injury (DILI) is a rare but potentially severe adverse drug event, which poses a major challenge for diagnosis in clinical practice and pharmacovigilance. Efforts have been made to establish diagnostic testing methods and biomarkers for safe diagnosis and differentiation from other liver diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Letter
Gastroenterology & Hepatology
Steven Trinh, Nicholas Batt, Rohit Sawhney, Amanda Nicoll
Summary: Drug-induced liver injury (DILI) is a rare cause of acute liver injury. Bjornsson et al. establish a European DILI registry to assess the clinical features and outcomes of DILI in several European countries. The authors highlight the need for reporting potential outcomes from pharmacotherapy to determine the role of medical therapy for DILI, as this information is currently lacking.
LIVER INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Katerina Roma, Salman Mohammed, Blake Sieck, Katrina Naik, Shahid Wahid
Summary: Alternative medicine supplements, such as kratoms, have become a significant cause of liver injury in the US. Reports of adverse events linked to kratom use are increasing, including liver injury, organ dysfunction, and even death. The need for increased regulation and public awareness of the risks associated with kratom is emphasized.
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Yi-Shin Huang, Ting-Tsung Chang, Cheng-Yuan Peng, Gin-Ho Lo, Chao-Wei Hsu, Chi-Tan Hu, Yi-Hsiang Huang
Summary: The study found that herbal and dietary supplements accounted for more than one-fifth of drug-induced liver injuries in Taiwan, and patients with HILI were more severe and had a higher mortality rate compared to those with CILI. Hepatitis B carriers, individuals with elevated baseline liver tests, and users of crude herbs may face a higher risk of HILI-related mortality. Prudent use of HDS is recommended for these high-risk individuals.
HEPATOLOGY INTERNATIONAL
(2021)
Review
Pharmacology & Pharmacy
Xinghui Li, Jiaqi Ni, Li Chen
Summary: This review focuses on the diagnosis, screening, and management of Acetaminophen (APAP)-induced liver injury (AILI), which is a significant cause of drug-induced liver injury and acute liver failure. It summarizes recent research progress, highlights current issues, and provides recommendations for future research.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Toxicology
Guillermo Quintas, Teresa Martinez-Sena, Isabel Conde, Eugenia Pareja Ibars, Jos Kleinjans, Jose Castell
Summary: DILI, an adverse toxic reaction associated with drug administration, is currently classified based on ALT and ALP values, but lacks accuracy. By integrating metabolomic information, a more accurate evaluation of DILI phenotypes can be achieved.
ARCHIVES OF TOXICOLOGY
(2021)
Review
Pharmacology & Pharmacy
Qiaoling Wang, Ang Huang, Jia-Bo Wang, Zhengsheng Zou
Summary: Chronic drug-induced liver injury poses a significant global challenge with difficulties in defining causality and effective treatment, affecting approximately 20% of DILI patients. Despite a lack of research on chronic DILI, clinical studies have provided insights into its incidence, special manifestations, and advancements in treatment, particularly in glucocorticoid therapy.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Gastroenterology & Hepatology
Xiaoyun Li, Jieting Tang, Yimin Mao
Summary: The epidemiology and aetiology of drug-induced liver injury (DILI) vary across different countries and populations. Antibiotics are the leading cause of DILI in Western countries, while traditional Chinese medicine is the primary cause in Eastern countries. The incidence of hepatotoxicity induced by herbal and dietary supplements is increasing globally. Although several risk factors for DILI have been described, there are no confirmed risk factors for all-cause DILI.
LIVER INTERNATIONAL
(2022)
Review
Immunology
Yan-zhong Han, Zhi-tao Ma, Ming-xi Zhou, Ming Niu, Xu Zhao, Yu-ming Guo, Xin-hua Song, Ya-wen Lu, Zhao-fang Bai, Zhen Li, Han Gao, Yong-kang Zhao, Jia-bo Wang, Xiao-he Xiao, Jing Jing
Summary: By using metabolomics analysis, it has been found that drug-induced liver injury with autoantibodies may not be a homogeneous group in terms of pathogenesis, including a subset with autoimmune hepatitis tendencies. This finding calls for further investigation.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Biochemical Research Methods
Hyun Kil Shin, Hang-Suk Chun, Sangwoo Lee, Se-Myo Park, Daeui Park, Myung-Gyun Kang, Sungbo Hwang, Jung-Hwa Oh, Hyoung-Yun Han, Woo-Keun Kim, Seokjoo Yoon
Summary: Drug-induced liver injury poses challenges in predictive toxicology due to complex metabolites and various mechanisms involved. ToxSTAR offers structural similarity-based analysis and prediction models for different DILI subtypes.
Article
Medicine, General & Internal
Dina Halegoua-DeMarzio, Victor Navarro, Jawad Ahmad, Bharathi Avula, Huiman Barnhart, A. Sidney Barritt, Herbert L. Bonkovsky, Robert J. Fontana, Marwan S. Ghabril, Jay H. Hoofnagle, Ikhlas A. Khan, David E. Kleiner, Elizabeth Phillips, Andrew Stolz, Raj Vuppalanchi
Summary: This case series study describes the clinical, histological, and HLA associations of turmeric-associated liver injury cases in the US Drug-Induced Liver Injury Network (DILIN). Ten cases of turmeric-associated liver injury were found, predominantly in women and with a strong linkage to HLA-B*35:01. Chemical analysis confirmed the presence of turmeric in all tested products. The study suggests an increasing trend of liver injury due to turmeric in the United States.
AMERICAN JOURNAL OF MEDICINE
(2023)
Article
Psychology, Multidisciplinary
Yi-Hui Liu, Yan Guo, Hong Xu, Hui Feng, Dong-Ya Chen
Summary: This study investigated anxiety and its influencing factors in patients with drug-induced liver injury (DILI). The results showed that patients with DILI may experience anxiety, especially mild anxiety. Anxiety in DILI patients is not associated with gender, age, occupation, or education level, but it may be related to the degree and type of liver injury. Anxiety does not affect the length of hospital stay or prognosis of DILI.
FRONTIERS IN PSYCHOLOGY
(2022)
